Lesson
Read the Azole Target and Pharmacophore
Systemic azoles inhibit fungal CYP51 and disrupt ergosterol synthesis; target binding, host CYP interactions and clinical activity require separate interpretation.
- CYP51
- Heme coordination
- Ergosterol depletion
- Agent-specific selectivity
- Resistance
The deposited posaconazole-Candida CYP51 complex provides one compound-specific example.
CYP51 inhibition changes sterol synthesis; it is not direct ergosterol binding.
Reduced ergosterol and accumulated methylated precursors alter the fungal membrane.
Shared target binding does not guarantee coverage, host CYP safety or the cause of failure.
Locate the molecular target
An azole ring nitrogen coordinates the heme iron of fungal CYP51. One direct structural example is the deposited Candida albicans CYP51-posaconazole complex, which records coordination of a posaconazole ring nitrogen to heme iron. This compound-specific observation supports the binding mechanism; it does not establish identical binding geometry, affinity or clinical activity for every azole.
Follow the pathway
CYP51, also called lanosterol 14 alpha demethylase, participates in the fungal sterol pathway. Its inhibition reduces ergosterol and allows methylated sterol precursors to accumulate, altering the fungal membrane. Distinguish this synthesis inhibition from amphotericin B binding to membrane ergosterol and from echinocandin inhibition of cell-wall glucan synthesis.
Separate selectivity from interaction risk
Fungal target selectivity and human CYP interaction risk are separate questions. Fluconazole labeling describes mammalian demethylation as less sensitive to inhibition, yet the drug also inhibits human CYP enzymes. Do not use the triazole ring or nitrogen count alone to claim interaction freedom or identical selectivity across agents; check the actual compound, enzyme evidence and current product interaction data.
Build a resistance model
Target alteration or overexpression and reduced target access, including efflux, can reduce azole susceptibility. Fluconazole labeling gives Candida ERG11 alteration or overexpression and MDR/CDR efflux as examples. These mechanisms are not proof of resistance in every failing infection. Review organism and appropriate susceptibility evidence, actual product delivery, exposure, infected site and source alongside prompt diagnostic and treatment reassessment when needed.
Quick check
Checking for saved practice…
Lesson
Choose the Agent, Organism, Site, and Phase
Fluconazole, itraconazole, voriconazole, posaconazole, and isavuconazole share a class but not one spectrum, indication set, or compartment role.
- Yeasts
- Molds
- Endemic fungi
- Disease phase
- Oral ketoconazole
Use organism and syndrome evidence rather than the shared azole name.
In vitro activity does not establish clinical exposure in every compartment.
Verify treatment, prophylaxis or transition requirements for the actual syndrome.
Check patient risks, feasible formulation and the exact safety restrictions.
Do not prescribe by class name
Fluconazole has useful activity against selected yeasts but no reliable Aspergillus or Mucorales activity. Mold-active triazoles also differ from each other: activity against Aspergillus does not establish activity against every mold, and the aspergillosis guideline specifically distinguishes voriconazole from agents used for mucormycosis. Match the actual organism, susceptibility and syndrome evidence rather than prescribing by class name.
Match the disease phase
Induction, step-down, consolidation, prophylaxis and chronic suppression require their own syndrome-specific evidence and exposure plans. A prophylaxis regimen is not automatically a treatment regimen. For example, an infection that develops during posaconazole prophylaxis requires diagnostic and treatment reassessment; simply continuing the prophylaxis plan does not establish appropriate treatment.
Respect the compartment
CNS, eye, urine, lung, bone, blood, valve and abscess disease create different delivery and source-control problems. In vitro activity does not prove adequate clinical exposure at every site. Check site-specific evidence and oral feasibility rather than assuming that a systemic ingredient or susceptible isolate settles the delivery question.
Restrict oral ketoconazole
Current oral ketoconazole labeling excludes onychomycosis, cutaneous dermatophyte and Candida infections. Its specified systemic fungal indications are restricted to patients who fail or cannot tolerate other therapies, with benefits judged to outweigh risks; acute or chronic liver disease is contraindicated. Keep topical treatment separate. If restricted oral use is considered, follow the label’s baseline evaluation, weekly ALT surveillance and liver-injury response instructions, and check QT interactions and adrenal risk. Normal baseline results do not remove the restriction or eliminate future injury.
Quick check
Checking for saved practice…
Lesson
Use Fluconazole Reliability Precisely
Fluconazole combines high oral bioavailability with primarily renal elimination, but species, dose, compartment, organ function, and interactions still govern success.
- Oral bioavailability
- Renal clearance
- Candida species
- Step-down
- QT and liver
High intrinsic bioavailability does not overcome vomiting, missed doses or inability to swallow.
Preserve the infection-specific initial exposure plan; assess ongoing clearance separately.
Repeated maintenance dosing and dialysis timing need product- and indication-specific review.
For candidemia step-down, verify stability, a susceptible isolate, negative repeat cultures and reliable oral delivery.
Use the oral route deliberately
Oral and intravenous exposure is often numerically comparable when gastrointestinal function and adherence are reliable. Vomiting, inability to swallow, and severe disease can still make oral delivery inappropriate.
Separate loading from maintenance
A loading dose rapidly fills the distribution volume, while renal function strongly influences maintenance exposure. Do not reflexively reduce a syndrome-specific loading dose solely because creatinine clearance is low. For repeated dosing, review maintenance and the dialysis schedule separately from the initial loading plan. The label gives a separate renal exception for single-dose vaginal-candidiasis treatment; do not apply that exception to a repeated invasive-infection course. A change to the oral route does not remove renal clearance. For adult repeated-dose maintenance, the label uses 100% of the recommended dose when creatinine clearance is above 50 mL/min and 50% when it is 50 mL/min or lower without dialysis. Hemodialysis patients receive 100% after each dialysis session, with reduced dosing on non-dialysis days according to creatinine clearance. Keep the indication-specific loading dose separate and obtain a dialysis-specific plan for modalities not covered by this table.
Require species context
Candida krusei is intrinsically resistant. Candida glabrata requires susceptibility-guided interpretation. For candidemia, fluconazole step-down requires clinical stability, a susceptible isolate and negative repeat blood cultures; also verify source control, the infection site and reliable oral delivery. A usually susceptible species does not guarantee that every isolate is susceptible.
Monitor beyond the kidney
Fluconazole can cause liver injury, QT prolongation, severe skin reactions, and clinically important CYP-mediated interactions. Renal elimination does not make it interaction free.
Tie the dose to the syndrome
A labeled adult vaginal-candidiasis regimen is a single 150 mg oral dose. It is not an invasive-infection regimen. For candidemia in selected nonneutropenic adults who are not critically ill and are unlikely to have a fluconazole-resistant Candida species, IDSA accepts intravenous or oral fluconazole as an alternative initial agent: 800 mg (12 mg/kg) loading, then 400 mg (6 mg/kg) daily. An echinocandin remains the recommended initial therapy in that guideline. These are indication-specific examples, not a universal fluconazole dose range. Tablets may be taken with or without food; verify the syndrome, susceptibility, renal maintenance plan and reliable delivery.
Quick check
Checking for saved practice…
Lesson
Treat Itraconazole Formulation as the Drug
Conventional capsules, oral solution, and newer enhanced-absorption products differ in exposure and cannot be treated as interchangeable containers.
- Capsules
- Solution
- Food and pH
- Heart failure
- TDM
Conventional capsule, solution and TOLSURA have distinct strengths, indications and regimens.
Use the full-meal capsule rule, solution without food when possible, or TOLSURA food and interaction plan.
Parent itraconazole and metabolite-sensitive measurements are different quantities; keep assay context visible.
Promptly assess edema, dyspnea or sudden weight gain and apply the exact product warning.
Name the complete product
Conventional capsules, oral solution, and enhanced-absorption products differ in bioavailability and approved use. Milligram-for-milligram substitution without review can destabilize exposure. Conventional SPORANOX capsules contain 100 mg; oral solution contains 10 mg/mL and gives greater exposure than capsules at the same dose. The US SUBA formulation TOLSURA contains 65 mg per capsule in a polymer matrix and is explicitly not interchangeable or substitutable with other itraconazole products. Its adult indications are blastomycosis, histoplasmosis, and aspergillosis when amphotericin B is not tolerated or has failed; it is not indicated for onychomycosis. Conventional SPORANOX capsules also have labeled onychomycosis use in non-immunocompromised patients, while the solution is indicated for oropharyngeal and esophageal candidiasis. Enhanced absorption does not establish better clinical outcomes or a universal dose-conversion ratio.
Teach opposing administration rules
Conventional capsules are taken with a full meal and depend on gastric acidity. Oral solution is taken without food when possible. Swallow conventional capsules whole immediately after a full meal; PPIs, H2 blockers and acid-neutralizing medicines can reduce their absorption. Separate acid-neutralizing medicines by at least two hours before or after the capsule. The capsule label describes increased absorption with non-diet cola in specific fasting, low-acidity studies; this does not establish a universal replacement for the full meal. For oropharyngeal or esophageal candidiasis, vigorously swish the solution in the mouth, 10 mL at a time, for several seconds and swallow. TOLSURA must be swallowed whole with food; do not chew, crush or break it. Its label describes increased exposure with acid-reducing medicines, including omeprazole, requiring adverse-reaction monitoring and possible dose reduction. Acid suppression, gastric surgery, nausea and tube feeding require product-specific intake and delivery assessment. Altered anatomy or a feeding tube does not establish one pharmacokinetic effect, capsule manipulation permission, or a universal feed-hold protocol.
Protect the heart
Itraconazole has negative inotropic potential and a boxed warning for congestive heart failure and cardiac effects. New edema, dyspnea, rapid weight gain, or exercise intolerance requires prompt evaluation and treatment reassessment. Do not use conventional SPORANOX capsules for onychomycosis in ventricular dysfunction or a history of heart failure. For other conventional-capsule indications, ventricular dysfunction requires a benefit that clearly outweighs the risk; oral solution is restricted in this setting to life-threatening or other serious infections. TOLSURA retains careful benefit-risk review and is not a cardiac-safety workaround. Patient instructions advise stopping itraconazole and contacting the healthcare provider immediately for heart-failure symptoms. Conventional capsule clinical labeling calls for discontinuation; solution and TOLSURA clinical warnings require reassessment of continued therapy and alternatives. Review interacting negative inotropes, including calcium channel blockers; felodipine and nisoldipine are contraindicated combinations.
Interpret the assay correctly
Variable absorption and active hydroxyitraconazole make concentration monitoring useful. Targets depend on timing, indication, formulation, and whether the laboratory reports parent drug alone or a combined value. Plan sampling using the infection-specific guidance, loading history and time needed for an interpretable result. IDSA aspergillosis guidance recommends TDM at steady state and patient-specific repeat monitoring when clinical status, absorption, adherence or interactions warrant it. The September 2026 severe-histoplasmosis guidance specifies monitoring after 1 to 2 weeks of itraconazole. A first loading dose is not itself proof of steady state. Check the exact product, administered doses, sampling time, interacting medicines, response and toxicity before changing therapy. Confirm whether the reported result measures itraconazole alone or includes hydroxyitraconazole. The histoplasmosis guidance notes that an established combined cutoff is lacking; aspergillosis guidance discusses different, indication-specific exposure interpretations. Historical FDA labeling also distinguishes parent-specific HPLC from a bioassay influenced by the active metabolite. Do not apply a parent-only target to a combined result or use one numerical target, conversion factor or sampling schedule for every infection.
Compare product-specific dose examples
The conventional SPORANOX capsule label begins adult blastomycosis or histoplasmosis dosing at 200 mg daily, with increments up to 400 mg daily; doses above 200 mg per day are divided. TOLSURA instead begins those labeled regimens at 130 mg daily, with increments up to 260 mg daily; doses above 130 mg per day are divided. These label examples illustrate product differences, not one preferred regimen for every form of histoplasmosis. Check current syndrome guidance and severity before prescribing. For life-threatening situations, the respective labels describe pharmacokinetically based three-day loading regimens of SPORANOX 200 mg three times daily or TOLSURA 130 mg three times daily; they explicitly state that clinical trials have not established these loading regimens. Conventional-capsule onychomycosis schedules also differ: toenails use 200 mg daily for 12 weeks; fingernail-only disease uses two one-week courses of 200 mg twice daily separated by three weeks off treatment. Do not transfer these nail schedules to TOLSURA, which is not indicated for onychomycosis, or ignore the cardiac restriction.
Quick check
Checking for saved practice…
Lesson
Control Voriconazole Variability
Voriconazole combines broad mold activity with nonlinear adult pharmacokinetics and CYP2C19 variability, requiring individualized exposure assessment and neurologic, hepatic, cutaneous and skeletal safety review.
- Nonlinear PK
- CYP2C19
- TDM
- Visual and CNS effects
- Long-term toxicity
Adult saturable metabolism can produce a disproportionate exposure rise; review dosing before an individualized change.
Verify concentration timing, actual administration, interactions and clinical response before acting on a result.
Use available CYP2C19 information with measured exposure; demographic categories alone do not assign metabolism.
Evaluate visual or CNS changes promptly; longer treatment requires skin, vision, bone-symptom and continuing-need review.
Coordinate voriconazole with meals and tube feeds
Give oral voriconazole on an empty stomach, at least one hour before or one hour after a meal. With tube feeding, hold the feed for one hour before and one hour after each dose. Write the dose and feeding times together so the interruption is visible to everyone administering them. This schedule is specific to voriconazole; do not copy it to itraconazole or posaconazole products.
Respect nonlinearity
Adult metabolism is saturable, so a dose increase can cause a disproportionate concentration rise. Incremental adjustment and repeat TDM are safer than assuming a linear dose-to-level relationship.
Measure the individual
CYP2C19 phenotype, inflammatory status, liver function, age, and interacting drugs contribute to variability. Adult observational evidence links greater inflammation with higher concentrations and reduced metabolism; exposure may change again as inflammation resolves. Reassess interpretable concentrations alongside symptoms, dose history and changing clinical status during and after severe inflammation. CRP alone does not establish the concentration or a fixed dose adjustment. A correctly timed concentration is more actionable than guessing metabolism from demographic characteristics.
Classify early toxicity
Transient visual disturbance is common, while hallucinations, confusion, severe visual symptoms, or other CNS effects can signal excessive exposure or another urgent cause. Reassess the symptoms, dose history, interacting medicines and an interpretable concentration promptly rather than diagnosing toxicity from a level alone. The VFEND patient label advises against night driving and against driving, operating machinery or other dangerous activities until the individual knows how treatment affects them. If treatment continues beyond 28 days, monitor visual acuity, visual field and color perception; prolonged visual adverse reactions have been reported. A transient early symptom does not remove the need to evaluate persistent or severe changes.
Plan for cumulative toxicity
Prolonged therapy has been associated with photosensitivity, cutaneous malignancy, periostitis and fluorosis. Avoid direct sunlight and use protective clothing and sunscreen with a high sun protection factor. Patients should contact the healthcare provider immediately for a new or worsening rash. Phototoxic reactions require dermatologic evaluation and consideration of discontinuation; if therapy continues despite phototoxicity-related lesions, use regular dermatologic assessment. The label calls for discontinuation when a lesion is consistent with a premalignant lesion, squamous cell carcinoma or melanoma, and when skeletal pain is accompanied by radiologic findings compatible with fluorosis or periostitis. Bone pain alone prompts evaluation rather than proving the syndrome. Review the treatment indication, alternatives, symptoms and relevant laboratory and imaging findings as duration increases; neither a drug level alone nor routine sun protection establishes safety.
Separate adult dosing from route conversion
For adult invasive aspergillosis, the VFEND label gives intravenous loading of 6 mg/kg every 12 hours for the first 24 hours, then intravenous maintenance of 4 mg/kg every 12 hours; the usual adult oral maintenance dose is 200 mg every 12 hours. Adults weighing less than 40 kg receive half the oral maintenance dose. Infection, response, interactions and organ function can require a different plan. This is not a milligram-for-milligram IV-to-oral conversion: labeling relates oral 200 mg every 12 hours to exposure from intravenous 3 mg/kg every 12 hours in healthy volunteers. Pediatric age and weight rules have separate regimens and must not be inferred from this adult example.
Apply organ and suspension instructions precisely
In adults with Child-Pugh A or B hepatic cirrhosis, use the usual loading regimen and half the maintenance dose. Child-Pugh C has no established pharmacokinetic dosing recommendation; use only when benefit outweighs risk with careful toxicity monitoring. Oral voriconazole does not require renal dose adjustment. With creatinine clearance below 50 mL/min, intravenous SBECD can accumulate: prefer oral therapy unless benefit-risk assessment justifies IV treatment, and monitor serum creatinine closely. For the reconstituted 40 mg/mL oral suspension, shake for about 10 seconds before each dose and measure with the supplied dispenser. Do not further dilute or mix it with medicines or flavoring. Store at room temperature, do not refrigerate or freeze, and discard unused suspension after 14 days. These preparation and storage rules do not replace the meal and feeding schedule.
Quick check
Checking for saved practice…
Lesson
Make Posaconazole Formulation Visible
Delayed-release tablets, oral suspension, and PowderMix differ in indication, eligibility, dosing, preparation, and exposure.
- Delayed-release tablet
- Oral suspension
- Non-substitution
- Food
- Pseudoaldosteronism
Verify indication, age, weight, and dosage form before selecting the regimen.
Swallow tablets whole; use the conventional suspension meal plan or PowderMix food and kit instructions.
Severe diarrhea or vomiting and suspension NG-tube delivery warrant breakthrough monitoring.
Review new hypertension or hypokalemia and correct electrolyte disturbances.
Stop unsafe substitution
Conventional posaconazole oral suspension is not substitutable with delayed-release tablets or PowderMix. A product switch requires a new indication, eligibility, dose, administration, and monitoring verification rather than a copied milligram amount. The February 2026 NOXAFIL label specifies delayed-release tablets for invasive aspergillosis treatment or high-risk prophylaxis in patients aged at least two years who weigh more than 40 kg. PowderMix covers those indications in children aged at least two years weighing 10 to 40 kg. Conventional oral suspension covers high-risk prophylaxis and oropharyngeal candidiasis in patients aged at least 13 years. Follow the exact product and indication rather than transferring one eligibility rule to every formulation. PowderMix is contraindicated in known or suspected hereditary fructose intolerance and requires its kit-specific preparation and provided notched-tip syringes.
Use the current tablet instruction
Delayed-release tablets are swallowed whole and may be taken with or without food. This differs from older generalized teaching that every posaconazole dose must accompany a meal. Do not divide, crush, or chew the tablets. For eligible patients who cannot eat a full meal, the label favors tablets over conventional suspension for prophylaxis because tablets generally provide higher exposure. Food flexibility does not guarantee absorption: monitor for breakthrough infection with severe diarrhea or vomiting. The tablet food study still found an exposure change with a high-fat meal.
Protect suspension absorption
Oral suspension is given with a full meal or, when needed, a nutritional supplement or acidic carbonated beverage. Give each conventional suspension dose during or within 20 minutes after a full meal. If a full meal is not possible and tablets or injection are not options, use the labeled liquid nutritional supplement or acidic carbonated beverage, such as ginger ale. If these cannot be tolerated either, consider an alternative antifungal or closely monitored suspension therapy. Shake well and use the provided measured dosing spoon. Assess poor intake, acid suppression, nausea, mucositis, diarrhea, and tube feeding before relying on oral delivery. Cimetidine and esomeprazole can lower suspension exposure; severe diarrhea or vomiting requires breakthrough monitoring. A healthy-volunteer NG-tube study found lower suspension exposure, but does not define every tube or continuous-feed protocol. Mucositis and nausea prompt intake assessment rather than a claimed uniform pharmacokinetic effect. PowderMix has separate with-food instructions and kit-specific preparation.
Recognize mineralocorticoid excess
Hypertension, hypokalemia, and metabolic alkalosis can signal posaconazole-associated pseudoaldosteronism. Blood pressure, potassium, bicarbonate, exposure, renin, aldosterone, and competing causes guide evaluation. The current NOXAFIL label reports new or worsening hypertension, hypokalemia, low renin and aldosterone, and elevated 11-deoxycortisol in the postmarket setting. The FDA clinical review completed in May 2021 also describes metabolic alkalosis and reports associated with supratherapeutic posaconazole exposure during long-term use. Monitor blood pressure and potassium, characterize the acid-base pattern, and review the exact product, dose, interacting medicines and other possible causes. Hormone results and an interpretable drug concentration may help contextualize a suspected case; this is not a required fixed panel or a universal concentration cutoff. Pre-existing hypertension and concomitant steroids can complicate attribution. The pattern warrants evaluation rather than proving causation in every patient. Label-listed management options include discontinuing NOXAFIL, using an appropriate alternative antifungal not associated with pseudoaldosteronism, or an aldosterone-receptor antagonist; correct electrolyte disturbances as needed. Do not wait for every specialized result before monitoring or correcting the clinical abnormalities.
Pair each adult regimen with its indication
For adult invasive aspergillosis treatment or high-risk prophylaxis, the labeled IV and delayed-release-tablet schedule is 300 mg twice on day 1, then 300 mg once daily from day 2. The label permits switching between these two forms without reloading after the prior loading history and ongoing schedule are verified. Conventional oral suspension has different regimens: high-risk prophylaxis uses 200 mg (5 mL) three times daily; oropharyngeal candidiasis uses 100 mg (2.5 mL) twice on day 1, then 100 mg once daily for 13 days; oropharyngeal candidiasis refractory to itraconazole or fluconazole uses 400 mg (10 mL) twice daily. The suspension schedules are not substitutes for the IV/tablet invasive-aspergillosis regimen. PowderMix is not recommended for adults and has separate pediatric weight- and indication-specific instructions.
Separate the IV vehicle warning from oral exposure
Avoid NOXAFIL injection when indexed eGFR is below 50 mL/min/1.73 m2 unless a benefit-risk assessment justifies its use. SBECD vehicle accumulation is expected in this setting; closely monitor serum creatinine and consider oral therapy if creatinine rises. Verify that the selected oral product can deliver adequate exposure. Severe renal impairment also warrants close breakthrough-infection monitoring with oral posaconazole products because exposure is variable. The posaconazole warning uses indexed eGFR; do not silently substitute the creatinine-clearance measure used in the IV voriconazole warning.
Quick check
Checking for saved practice…
Lesson
Translate Isavuconazonium Without Error
Isavuconazonium is a water-soluble prodrug whose active-equivalent mass, loading sequence, route equivalence, interactions, and QT shortening require precise translation.
- Prodrug
- Active equivalent
- Loading
- Route switch
- QT shortening
372 mg isavuconazonium sulfate is equivalent to 200 mg active isavuconazole; identify which amount the order uses.
Confirm six doses every eight hours; start maintenance 12 to 24 hours after the last loading dose.
IV and oral formulations are bioequivalent; a verified switch does not automatically restart loading.
Familial short QT syndrome is contraindicated; review interacting medicines, liver status and the clinical indication.
Read both mass conventions
A 372 mg dose of isavuconazonium sulfate is equivalent to 200 mg of active isavuconazole. Orders, labels, handoffs, and calculations must state the intended convention clearly.
Complete the adult loading sequence
Adult treatment uses 372 mg every 8 hours for six doses, then 372 mg once daily. Maintenance begins 12 to 24 hours after the last loading dose.
Switch routes without resetting exposure
Oral and intravenous formulations are bioequivalent. A verified route change continues the schedule and does not automatically restart all six loading doses. CRESEMBA does not require dose adjustment for renal impairment, including end-stage renal disease. Severe hepatic impairment has not been studied; use only when benefits outweigh risks and monitor for adverse reactions. Renal flexibility does not establish safety in severe liver disease.
Distinguish QT direction
Isavuconazole shortens QT in a concentration-related manner and is contraindicated in familial short QT syndrome. QT direction alone does not erase interaction, liver, or patient-specific risk.
Protect the capsule and infusion route
Take capsules with or without food and swallow them whole; do not open, crush, chew or dissolve them. Keep each capsule in its blister until use to protect it from moisture, and do not puncture or swallow the desiccant packet. IV administration requires an in-line filter with a pore size of 0.2 to 1.2 micrometers. Current labeling also permits the injection formulation through a nasogastric tube under its specific preparation instructions in eligible patients; the capsules are not for nasogastric administration. Route flexibility does not authorize capsule manipulation or an improvised preparation.
Quick check
Checking for saved practice…
Lesson
Own the Interaction From Start Through Stop
Triazoles can inhibit CYP enzymes, depend on them for clearance, encounter strong induction, and alter electrophysiologic risk.
- Perpetrator
- Victim
- Induction
- QT burden
- Offset
Identify how the triazole and co-medication can change each other’s exposure.
Distinguish contraindication, avoidance and a product-specific monitored plan.
Previously reduced substrates may need concentration-guided dose reassessment.
Document who reviews levels, symptoms and the next dose or monitoring change.
Review both directions
A triazole may raise a narrow-therapeutic-index substrate while another medicine changes triazole exposure. Check both directions and the exact product instructions before the first dose. Contraindicated combinations, combinations best avoided, and combinations with monitoring or dose-management instructions are distinct. The rule may also depend on the co-medication’s indication and treatment phase; an oncology drug name alone is not a complete plan.
Treat strong induction as failure risk
Rifamycins, selected anticonvulsants, St John's wort, and other strong inducers can substantially reduce exposure to susceptible mold-active triazoles. Review the exact combination: a concentration measurement does not waive a contraindication, and a management instruction for one interacting drug cannot be transferred to another. Select an appropriate alternative or a product-specific, supervised plan and reassess when interacting medicines change.
Review the full QT context
Several triazoles carry QT-prolongation precautions, while isavuconazole shortens QT and is contraindicated in familial short QT syndrome. Review QTc, relevant congenital syndromes, heart rate, structural heart disease, potassium, magnesium, calcium and co-medications. Correct relevant electrolyte disturbances rather than giving replacement automatically when values are normal. QT shortening does not remove other safety or interaction requirements.
Plan the interaction offset
A substrate dose reduced when an azole starts may become inadequate when inhibition resolves after discontinuation. Document the responsible clinician, monitoring plan and dose-reassessment trigger. For example, when voriconazole stops after tacrolimus was reduced, VFEND labeling calls for frequent tacrolimus concentration monitoring and dose increases as necessary. Neither leaving the reduced dose permanently fixed nor automatically restoring the old dose without assessing current exposure closes the transition safely.
Quick check
Checking for saved practice…
Lesson
Turn Every Measurement Into an Action
Concentration, liver, kidney, electrolyte, ECG, skin, vision, bone, and reproductive assessments become useful only when timing and action thresholds are defined.
- TDM
- Liver
- Kidney and vehicle
- Electrolytes and ECG
- Pregnancy and lactation
Identify the agent, product and a relevant exposure, efficacy or toxicity concern.
Record actual administration, last dose, sample time and steady-state context.
Use the appropriate assay and agent-specific target with response, adverse effects and interactions.
Reassess delivery or treatment as indicated and specify follow-up ownership.
Use TDM where variability matters
Itraconazole and voriconazole have clinically important exposure variability. Select TDM according to the agent, formulation and clinical setting rather than ordering it solely because a drug is a triazole. Posaconazole delivery, interactions, failure or toxicity may also create an actionable concentration question; evidence and routine monitoring needs differ among its formulations and among other agents. Record the actual dosing history, formulation, sample timing and assay, and interpret the result with infection response and adverse effects. For example, a concentration drawn at an undocumented time after missed itraconazole doses cannot be treated automatically as an interpretable steady-state trough or justify an automatic dose increase.
Monitor the liver dynamically
Every systemic triazole can cause clinically important liver injury. Normal baseline tests do not prevent injury after treatment starts. Follow the exact product’s baseline and on-treatment laboratory instructions, accounting for symptoms, duration, hepatic function, co-medications and trends. Abnormal tests or new symptoms require reassessment for more severe injury and the product’s treatment actions; do not wait for a scheduled blood draw when concerning symptoms develop or impose one fixed monitoring interval on the entire class.
Separate kidney mechanisms
Fluconazole is cleared primarily as unchanged drug by the kidneys; multiple-dose instructions distinguish the initial loading dose, maintenance adjustment and dialysis context. Selected intravenous formulations raise a different concern about accumulation of the solubilizing vehicle SBECD. Identify the exact product and the renal measure used in its instructions rather than transferring one renal rule to every agent or route. When an oral alternative is considered, assess whether it can deliver adequate exposure and continue the required clinical monitoring.
Use current reproductive information
Pregnancy and lactation decisions require current agent-specific narrative labeling, dose, route, duration, disease severity, alternatives, and specialist input. Obsolete pregnancy letters are not an adequate decision system. Fluconazole’s label distinguishes prolonged high-dose first-trimester reports from lower-dose observational signals; neither supports assuming a single systemic dose is risk-free. Itraconazole’s pregnancy restriction differs between onychomycosis and serious systemic infection. Voriconazole and posaconazole describe fetal risks and missing or limited human pregnancy data. Lactation instructions also differ: VFEND and NOXAFIL describe consideration of clinical need and potential infant effects, while CRESEMBA directs discontinuation of breastfeeding during treatment. Missing human data does not establish safety, and pregnancy and lactation require separate assessment.
Quick check
Checking for saved practice…
Lesson
Close the Triazole Clinical Loop
Successful therapy joins diagnosis, organism, site, source, exact product, exposure, toxicity, response, transition, and long-term ownership.
- Baseline
- Breakthrough audit
- Step-down
- Longitudinal safety
- Educational boundary
Confirm syndrome, organism, site, source and the exact product plan.
Review actual administration, adherence and interacting medicines.
Evaluate symptoms and appropriate exposure evidence; breakthrough needs prompt clinical review.
Apply syndrome-specific readiness criteria and assign follow-up responsibility.
Verify the baseline
Confirm syndrome, host, organism evidence, appropriate susceptibility interpretation, infected site and source, exact product, dose and administration, organ function, interactions, reproductive context and monitoring responsibility. ECG, electrolytes and concentration assessment depend on the actual agent and clinical question; baseline verification is not one universal laboratory panel.
Audit breakthrough broadly
Wrong organism, resistance, poor absorption, formulation error, interaction, nonadherence, inadequate dose, uncontrolled source and limited site exposure can contribute to failure. Do not equate breakthrough with resistance alone. For suspected breakthrough invasive mold disease, review delivery and interpretable concentrations alongside prompt clinical and diagnostic assessment and individualized treatment reassessment. Do not delay necessary management while waiting for every audit result; the aspergillosis guideline emphasizes prompt diagnosis, illness severity and local epidemiology.
Require step-down readiness
Before a high-risk oral transition, verify the actual syndrome’s readiness criteria, appropriate active oral agent, reliable product exposure, interaction plan and follow-up. In candidemia, the guideline specifies clinical stability, a susceptible isolate and negative repeat blood cultures for step-down; source assessment and reliable delivery remain essential. For example, improving fever alone does not establish candidemia step-down readiness if cultures remain positive or the proposed oral product cannot be taken reliably. Do not transfer candidemia’s criteria unchanged to every fungal syndrome.
Update the long-term plan
Duration and changes in physiology or medicines can alter the safety plan. Reconcile medications and reassess continuing need, relevant laboratory trends, symptoms and exposure over time. Liver, cardiac, electrolyte, skin, vision, bone, heart-failure and blood-pressure review are agent- and context-specific; the list is not a requirement for every test at one fixed interval for every triazole. New findings require reassessment of the actual drug and clinical situation.
Quick check
Checking for saved practice…
Module practice
Check the connections.
Each attempt draws 10 questions from the complete 176 question bank.
Each attempt draws a fresh set and rearranges the answer choices.
References
Current clinical foundation.
Core source material was synthesized with the following contemporary guidance. Verify local policy and current guidance before applying clinical information.
- DailyMed Fluconazole Label, updated 2025
- DailyMed SPORANOX capsule prescribing information, July 2026
- DailyMed itraconazole oral solution prescribing information, January 2025
- DailyMed Voriconazole Label, updated 2025
- DailyMed NOXAFIL prescribing information, February 2026
- DailyMed Cresemba Label
- DailyMed Oral Ketoconazole Label
- IDSA Aspergillosis Guideline, 2016
- IDSA Candidiasis Guideline
- IDSA Histoplasmosis Guideline, 2025 and September 2026 update
- DailyMed TOLSURA prescribing information, October 2024
- FDA TOLSURA multidisciplinary review, 2018
- FDA SPORANOX historical assay information, 2012
- FDA NOXAFIL multidisciplinary review, May 2021 (historical safety review)
- DailyMed VFEND prescribing information and patient counseling
- Veringa et al., voriconazole metabolism and inflammation, prospective observational study, 2017
- Wang et al., possible periostitis during prolonged voriconazole after lung transplantation, case-series abstract, 2009
- FDA CRESEMBA other reviews, 2015 (historical prodrug-solubility source)
- FDA pregnancy and lactation labeling questions and answers
- RCSB PDB 5FSA: experimental Candida CYP51-posaconazole structure, Hargrove et al., 2017